Judge Dyk Explains Takeda Loss In IP Fight Over Hemlibra

By Britain Eakin (January 21, 2022, 9:17 PM EST) -- U.S. Circuit Judge Timothy B. Dyk has unsealed his opinion in a Delaware federal court case explaining why he found a Takeda Pharmaceutical Co. Ltd. unit's antibody patent was too broad to meet the enablement requirement, ultimately letting Roche subsidiary Genentech off the hook for infringing with its blockbuster hemophilia drug Hemlibra.

The Jan. 13 opinion from U.S. Circuit Judge Timothy B. Dyk — who has been overseeing the case since 2018 — was unsealed Wednesday. It said the experimentation required to figure out which antibodies work would be like "a search for a needle in a haystack," and because of...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!